Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Tyrrell

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Clinical Radiology|September 1, 1977
The role of ultrasound in the assessment and treatment of abdominal metastases from testicular tumoursC J Tyrrell, D O Cosgrove, V R McCready, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1994
Chemotherapy induced myocardial fibrosisM P Callaway, C J Tyrrell, M P Williams, et al.
British Journal of Urology|October 1, 1989
Cystic prostatic carcinomaM G Wyatt, T J Clarke, C J Tyrrell, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?A V Kaisary, P Iversen, C J Tyrrell, et al.
European Urology|January 1, 1995
A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study GroupA V Kaisary, C J Tyrrell, C Beacock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Intravenous pamidronate: infusion rate and safetyC J Tyrrell, M Collinson, E L Madsen, et al.
Clinical Radiology|July 1, 1986
Results of treatment of primary breast carcinoma by radical radiotherapy with artificial pneumothoraxA Benghiat, C J Tyrrell, H E Davidson, et al.
World Journal of Urology|May 21, 2003
The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary studyC J Tyrrell, G M Blake, P Iversen, et al.
European Urology|February 21, 1998
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study GroupC J Tyrrell, L Denis, D Newling, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 1, 1991
Haematological toxicity compromises MOPP/ABVD chemotherapy in Hodgkin's diseaseM J Goodrick, F Daniel, A G Prentice, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Clinical Radiology|September 1, 1977
The role of ultrasound in the assessment and treatment of abdominal metastases from testicular tumoursC J Tyrrell, D O Cosgrove, V R McCready, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1994
Chemotherapy induced myocardial fibrosisM P Callaway, C J Tyrrell, M P Williams, et al.
British Journal of Urology|October 1, 1989
Cystic prostatic carcinomaM G Wyatt, T J Clarke, C J Tyrrell, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?A V Kaisary, P Iversen, C J Tyrrell, et al.
European Urology|January 1, 1995
A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study GroupA V Kaisary, C J Tyrrell, C Beacock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Intravenous pamidronate: infusion rate and safetyC J Tyrrell, M Collinson, E L Madsen, et al.
Clinical Radiology|July 1, 1986
Results of treatment of primary breast carcinoma by radical radiotherapy with artificial pneumothoraxA Benghiat, C J Tyrrell, H E Davidson, et al.
World Journal of Urology|May 21, 2003
The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary studyC J Tyrrell, G M Blake, P Iversen, et al.
European Urology|February 21, 1998
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study GroupC J Tyrrell, L Denis, D Newling, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 1, 1991
Haematological toxicity compromises MOPP/ABVD chemotherapy in Hodgkin's diseaseM J Goodrick, F Daniel, A G Prentice, et al.
Pageof 5